The Libertarian Case for Most Favored Nation Pricing That's Hard to Argue With

Описание: American taxpayers fund somewhere between 80 and 90 percent of global pharmaceutical R&D, and the return on that investment is paying 3 to 5 times more for the same drugs that France, the UK, and Germany are buying at a fraction of the American price. A generation that grew up watching that arrangement play out is now choosing between EpiPens and rent and wondering if homeownership will ever be realistic for them.

The Most Favored Nation pricing argument doesn't require being anti-market or anti-profit. It requires the market to produce something resembling a fair outcome for the people funding it — and by any honest measure, the current arrangement isn't that.

The podcast Big Pharma doesn't want you listening to — new episodes every week at bustbigpharmapodcast.com/Platforms

#DrugPricing #HealthcareReform #BigPharmaExposed #PharmaGreed #CorruptionWatch